About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Dr. Stephan Rietiker elected as new Chairman of the Board of MetrioPharm AG

  • Dr. Rietiker has considerable experience in the life sciences industry, including leadership positions in global pharmaceutical and medical device companies, and has overseen multiple major company acquisitions.

Zurich, April 23, 2025 MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the new Board of Directors unanimously elected Dr. Stephan Rietiker as Chairman at its constituent meeting.

“I would like to thank the members of the Board of Directors for their vote and the trust they have placed in me,” commented Dr. Rietiker. ”Our common goal will be a successful clinical development and swift commercialization of the asset MP1032. The company is in a promising position to do so. We would like to thank all the outgoing board members for their commitment over the past years, which has achieved convincing results, including in the COVID-19 indication. It will be our task to effectively build on this and I personally look to the work ahead with optimism.”

“With Dr. Rietiker, MetrioPharm AG has gained a highly experienced pharmaceutical expert who has a successful track record in management and as an investor,” commented MetrioPharm CEO Thomas Christély. ”He has an in-depth knowledge of the European and US markets and can actively support the company in addressing upcoming challenges on the path to market. On behalf of the management and the team of MetrioPharm AG, I welcome him and all the newly elected members of the Board of Directors.”

Dr. Stephan Rietiker, a trained physician qualified to practice medicine both, in Switzerland and the United States, began his career as a physician in Switzerland. He has since gone on to establish himself as an acknowledged expert and leader in healthcare and technology. His executive positions with various global pharmaceutical and medical technology companies including Roche, Boehringer Mannheim, Schering Plough, Covance, Centerpulse and LifeWatch have earned him a strong reputation as a rounded and successful manager and turnaround specialist with extensive experience in the U.S. market. Following a turnaround of LifeWatch and a successful sale of the company to BioTelemetry Inc., Dr. Rietiker joined the Board of BioTelemetry where he vigorously supported the acquisition of BioTelemetry Inc by Philips for USD 2.8 Bio in 2021. In 2022, he incorporated EpiLunar Partners AG based in Zug, Switzerland, to invest in and develop marketable breakthrough solutions in the digital health space.

###

About MetrioPharm AG

MetrioPharm AG is a private, clinical-stage biotech company focused on therapies for inflammatory and infectious diseases.

MetrioPharm targets the modulation of immune metabolism with first-in-class self-regulating drug candidates. The Company ́s platform has generated small-molecule metabolic modulators that have demonstrated pre-clinical and clinical efficacy in a wide range of inflammatory and infective diseases with an outstanding safety profile.

Based on this core technology, MetrioPharm has created a pipeline of disease-specific drug combinations targeting inflammatory, autoimmune, and degenerative diseases. Preclinical and clinical efficacy data have been obtained in multiple sclerosis, arthritis, sepsis, inflammatory bowel disease and psoriasis. The Company is currently exploring several orphan indications with Duchenne muscular dystrophy as its lead indication.

In a second line of development, MetrioPharm is developing its technology to target infectious diseases such as COVID-19 – also as a proof of concept to improve pandemic preparedness. Supported by a grant from the European Health Emergency Preparedness and Response Authority (HERA), a Phase IIa exploratory study evaluated the effect on hospitalized COVID-19 patients. The study confirmed the good clinical safety profile of MP1032 and demonstrated compelling efficacy data.

The Company is headquartered in Zurich and has a subsidiary for R&D activities in Berlin.

Forward-looking statements

This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm AG's assessment as of the date of this release. Such forward- looking statements are neither promises nor guarantees but are subject to numerous risks and uncertainties. No liability or warranty, and no claim, if any, is made with respect to the timeliness, accuracy or completeness of such data and information, and no reliance should be placed on such data and information, either explicitly or impliedly.

Contacts

MetrioPharm
Corporate Communications & Press Relations
presse@metriopharm.com
Phone +41 44 552 7198

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners      
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68



Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.